OVERVIEW OF TRANSFUSION GUIDELINES

Sai Karan Vamsi Guda D.O.
OSU IM - PGYIII
OVERVIEW

• Background
• Methods
• Results
• Discussion
• Limitation
• AABB guideline recommendations
• Massive Transfusion Protocol (MTP)
• Thromboelastography (TEG)
• Transfusion trend changes a OSUMC
BACKGROUND
• 100 million units PRBC obtained worldwide/ year

• 13 million in the USA

• There remains substantial variation in the practice of transfusing patients.

• Physicians often use either hemoglobin level or the symptoms of anemia to decide when to transfuse.
• Transfusion guidelines are to be designed to optimize clinical outcomes and to avoid non-clinically indicated transfusions.

• The criticisms of the guidelines released by AABB in 2012 were that the RCTs were small studies (median: 120 patients; range: 22 - 2016 patients; total n=6264 in 19 RCT) and had high risk of bias.

• Since then however there has been a tremendous increase in the RCT assess PRBC guidelines.
Relative safety of transfusion reactions is described in (Table 1).
Unnecessary transfusion expose patients to increased risk and costs without benefit.
A liberal strategy is to be utilized if there’s evidence for improvement in outcomes.
METHODS
Methods

**AIM:** These guidelines provide recommendations for the clinicians caring for hospitalized adult patients who are hemodynamically stable and are candidates for RBC transfusions.

The committee members had no substantial conflicts of interest, who included:

- Former members of the AABB clinical transfusion medicine committee, experts appointed by professional organizations as subject matter experts (American Association for the Surgery of Trauma; Society of Critical Care Medicine; American College of Cardiology; American Society of Anesthesiologists; and American Society of Hematology), a patient representative. The physician panel included primarily pathologists, hematologists, anesthesiologist, cardiologist, internist, critical care medicine physician, trauma or acute care surgeon, and a Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologist
METHODS

• The guidelines were developed based on separately published updated systematic reviews of the literature on transfusion thresholds.

• Literature searches of RCTs evaluating transfusion thresholds from 1950 through May 2016.

• The systematic review included RCTs in which the transfusion groups were assigned on the basis of a clear transfusion trigger or threshold, which was described as hemoglobin or hematocrit level that had to be reached before a RBC transfusion was administered.

• Trials of patients treated surgically, medically, as those involving adults or children (but not neonates) were included.
METHODS

- The primary outcome was mortality
  - 30-day mortality for transfusion thresholds

- Secondary outcomes for transfusion thresholds included
  - Morbidity, hemoglobin levels (the timing of measurement varied among trials) and the number of PRBC units transfused.
    - Nonfatal myocardial infarction,
    - Pulmonary edema or congestive heart failure
    - Stroke
    - Thromboembolism
    - Renal failure
    - Infection
    - Re-bleeding
    - Mental confusion
• Each RCT was assessed for the risk of bias for sequence generation, allocation concealment, blinding, and incomplete outcome data

• Statistical heterogeneity was assessed using both $I^2$ and $\chi^2$ tests.
• When the evidence suggested no harm from withholding transfusion, the committee was prepared to make a strong recommendation for a restrictive threshold.

• When evidence regarding harm was uncertain, the committee elected not to make a recommendation.

• “When deciding to transfuse an individual patient, it is good practice to consider not only the hemoglobin level, but the overall clinical context and alternative therapies to transfusion.”

• Variables to take into consideration include the rate of decline in hemoglobin level, intravascular volume status, shortness of breath, exercise tolerance, light headedness, cardiac chest pain, hypotension or tachycardia unresponsive to fluid challenge, and patient preferences.
RESULTS
Methods

• 3557 records were evaluated
• 3519 – only abstracts were removed
• 38 full text articles with 11 trial protocols were further evaluated and after removing all non RCT studies ended up with 31 RCTs which included both Qualitative and Quantitative Data analysis.
• 12587 patients
• Transfusion strategy did not influence the risk of cardiovascular events, including myocardial infarction, congestive heart failure, or stroke.
Thirty-day mortality is the primary outcome, and 23 trials reported data (N = 10,537 participants).

- There was no difference in the 30-day mortality between restrictive and liberal transfusion strategies.

- Subgroup analysis of 30-day mortality: restrictive threshold of 8 g/dL to 9 g/dL versus 7 g/dL
  - 14 trials, with 4772 participants, used a restrictive threshold of 8 g/dL to 9 g/dL.
  - 9 trials, with 5765 participants, used a 7 g/dL restrictive threshold.
  - The test for subgroup differences was not significant (p= 0.56), indicating that there was no difference in the mortality risk between the two thresholds.
Subgroup analyses of 30-day mortality: clinical specialty

The clinical specialty used in the trials: cardiac surgery, orthopedic surgery, vascular surgery, acute blood loss or trauma, gastrointestinal (GI) bleeding, critical care, acute myocardial infarction, or hematological malignancies.

In two trials that reported mortality at 30 days in 2221 participants with acute blood loss or trauma (GI bleeding), the mortality was significantly lower using the restrictive strategy compared with the liberal strategy.

Two trials recruited 154 participants who had acute myocardial infarction and evaluated mortality after random allocation; for this subgroup, the mortality risk was higher in the restrictive strategy group than in the liberal strategy group.
• **No difference** between the restrictive and liberal transfusion strategies
  - Cardiac events: 9 trials; 4849
  - Myocardial infarction (fatal and non-fatal): 16 trials; 8303
  - Congestive heart failure: 12 trials; 6257
  - Cerebrovascular accident: 13 trials; 7343
  - Rebleeding: 6 trials; 3108. The risk of developing recurrent bleeding associated with restrictive transfusion was about half that of liberal transfusion.
• **No difference** between the restrictive and liberal transfusion strategies

  • Infection:
    • Sepsis/bacteremia: 7 trials; 3963
    • Pneumonia: 14 trials: 6277
    • Pneumonia or wound infection: 14 trials; 9574
  • Thromboembolism: 10 trials; 4019
  • Renal failure: 10 trials; 5929
  • Mental confusion: 6 trials; 1344
  • Functional recovery: 4 trials reported functional outcomes in orthopedic surgery participants.
DISCUSSION
• The results of the meta-analyses indicated that restrictive transfusion strategies led to a reduction of more than one-third (43%) in the number of participants receiving at least one unit of blood.

• Most importantly, the meta-analyses provided no evidence that restrictive transfusion policies harmed the participants or that they benefited from the use of liberal transfusion policies, within the parameters defined in the trials.

• Across nearly all subgroups, the results indicated that risk of death and other adverse events were not impacted by either liberal or restrictive transfusion thresholds.
In acute blood loss and those with acute myocardial infarction, mortality was influenced by a liberal or restrictive transfusion strategy – 30-day mortality between the subgroups was not significant (P = 0.13).

- Participants enrolled with acute myocardial infarction demonstrated different results for 30-day mortality.

- Two small trials “Liberal Versus Restrictive Transfusion Thresholds For Patients With Symptomatic Coronary Artery Disease” and “the CRIT Randomized Pilot Study” included these participants (N = 154) for which the 30-day mortality was 3.88 times higher in the restrictive transfusion group than in the liberal transfusion group.

- In participants with gastrointestinal bleeding a restrictive transfusion strategy was associated with a 35% lower risk of 30-day mortality than a liberal transfusion strategy.
The compared the risk of infection was analyzed in three ways but did not find evidence of a reduced risk of infection associated with restrictive transfusion.

These results varied significantly from previous analyses provided by Rohde et al in 2014 where a restrictive strategy was attributed to decreasing the risk of infection.

The studies evaluating functional capacity were not analyzed equally as they did not use the same measure for functional capacity.
LIMITATIONS

• Assigning a single level of bias to multiple outcomes was not possible because of variable methods.

• Some studies were not appropriately blinded, while others demonstrated allocation bias.

• There is subjective interpretation of severity of cardiovascular events.

• All these trials evaluated patients receiving PRBC inpatient where endpoints are different compared to outpatient.

• Pathophysiological application of hbg concentration as a marker for tissue oxygenation is inadequate.
RECOMMENDATIONS
RECOMMENDATIONS

• The AABB recommends a restrictive RBC transfusion threshold in which the transfusion is not indicated until the hemoglobin level is 7 g/dL for hospitalized adult patients who are hemodynamically stable, including critically ill patients, rather than a liberal threshold when the hemoglobin level is 10 g/dL; (strong recommendation, moderate quality evidence).
  • 6 trials (TRICC/TRISS) conducted with critical care patients
  • Threshold for restrictive was 7 g/dL; liberal 9 – 10 g/dL
For patients undergoing orthopedic surgery or cardiac surgery and those with preexisting cardiovascular disease, the AABB recommends a restrictive RBC transfusion threshold hemoglobin level of 8 g/dL; (strong recommendation, moderate quality evidence).

- Orthopedic: 10 trials; Restrictive threshold was 8; Liberal threshold 10 g/dL
- There was no difference in ability to walk, multiple measures of function, fatigue, and length of hospital stay
- CVD: 5 trials; Restrictive threshold was 8; Liberal threshold 10 g/dL
- TRICS III currently in process is evaluating threshold of 7.5 g/dL
RECOMMENDATIONS

• These recommendations apply to all but the following conditions for which the evidence is insufficient for any recommendation: **acute coronary syndrome**, **severe thrombocytopenia** (patients treated for hematological or oncological disorders who at risk of bleeding), and **chronic transfusion–dependent anemia**.
MASSIVE TRANSFUSION PROTOCOL
MASSIVE TRANSFUSION PROTOCOL

• Definition:
  • Replacement of one entire blood volume within 24 h
  • Transfusion of >10 units of packed red blood cells (PRBCs) in 24 h
  • Replacement of 50% of total blood volume (TBV) within 4 h.
  • Greater than 150 cc/min blood loss
<table>
<thead>
<tr>
<th>Class of haemorrhagic shock</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood loss (mL)</td>
<td>Up to 750</td>
<td>750–1500</td>
<td>1500–2000</td>
<td>&gt; 2000</td>
</tr>
<tr>
<td>Blood loss (% blood volume)</td>
<td>Up to 15</td>
<td>15–30</td>
<td>30–40</td>
<td>&gt; 40</td>
</tr>
<tr>
<td>Pulse rate (per minute)</td>
<td>&lt; 100</td>
<td>100–120</td>
<td>120–140</td>
<td>&gt; 140</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Normal</td>
<td>Normal</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td>Pulse pressure (mm Hg)</td>
<td>Normal or increased</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td>Respiratory rate (per minute)</td>
<td>14–20</td>
<td>20–30</td>
<td>30–40</td>
<td>&gt; 35</td>
</tr>
<tr>
<td>Urine output (mL/hour)</td>
<td>&gt; 30</td>
<td>20–30</td>
<td>5–15</td>
<td>Negligible</td>
</tr>
<tr>
<td>Central nervous system/mental status</td>
<td>Slightly anxious</td>
<td>Mildly anxious</td>
<td>Anxious, confused</td>
<td>Confused, lethargic</td>
</tr>
</tbody>
</table>
RECOMMENDATIONS
RECOMMENDATIONS

• It is recommended that institutions develop Massive Transfusion Protocols (MTP) that included dose, timing and ratio of blood component therapy for use in trauma patients with, or at risk of, critical bleeding requiring massive transfusion (Grade C).

• In Patients with critical bleeding requiring massive transfusion, hemoglobin concentration should be interpreted in the context of hemodynamic status, organ perfusion and tissue oxygenation (PP).

• The patient having a critical bleed is to be adequately resuscitated and surgical interventions sought out.
• The routine use of rFVIIa in trauma patients with critical bleeding requiring massive transfusion is not recommended because of its lack of effect on mortality (Grade B) and variable effect on morbidity (Grade C)
  • rFVIIa should be used only after surgical hemostasis ad component therapy have failed to control critical bleeding
  • If is to be used an initial dose of 90 ug/kg is reasonable

• In trauma patients with critical bleeding requiring massive transfusion, an RBC: FFP ratio of ≤ 2:1 is associated with reduced mortality
  • 4 level III studies examined the effect of FFP or platelet transfusion on mortality/morbidity; ? Survivor bias; Need to see use of fibrinogen or cryoprecipitate
THROMBOELASTOGRAPHY
Thromboelastography

- In critically bleeding patients requiring massive transfusion, there is insufficient evidence to identify an INR (PT/APTT), fibrinogen level or platelet count to trigger a blood component transfusion
  - There is unavoidable delay in provision of laboratory result there is an increase in the use of *thromboelastography* (TEG).

- TEG is a method of testing efficiency of coagulation in blood.

- It was designed to overcome the static nature of other assessments such as INR/PT/PTT/Fibrinogen/D-Dimer

- Typically used during obstetric, cardiac and liver transplant surgeries
Thromboelastography

- Parameters of measurements
  - **R-time**: time of latency from initiation of test to initial fibrin formation
  - **K-time**: time taken to achieve certain level of clot strength
  - **alpha-angle**: measures speed of fibrin build up and cross linking
  - **Maximum amplitude (MA)**: measure ultimate strength of the fibrin clot.

- Deficient coagulation factors: prolonged *r, k times* and decreased *MA and alpha angle*

- Hypercoagulable states: *k, r times* are decreased with increase of *MA and alpha angle*.
RECOMMENDATIONS
RECOMMENDATIONS

• Recommended dose of blood components:
  • FFP: 15mL/kg
  • Platelets: 1 adult therapeutic dose
  • Cryoprecipitate: 3 – 4 g
  • rVIIa: 90 ug/kg

• In trauma patients with or at risk of significant hemorrhage, tranexamic acid should be considered
  • Loading dose: 1 g over 10 minutes
  • Followed by infusion of 1g over 8 hrs
OSU TRANSFUSION TREND
OSU PRBC

TRANSFUSION TRENDS

Transfusion Trend From 2008 - 2017

Total Number Of PRBC Transfusions, Hb 8-12 g/dL From 2012 To 2017

<table>
<thead>
<tr>
<th>Hemoglobin level at transfusion</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.5-11.9</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>11.0-11.4</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>10.5-10.9</td>
<td>16</td>
<td>4</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>10.0-10.4</td>
<td>14</td>
<td>10</td>
<td>18</td>
<td>22</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>9.5-9.9</td>
<td>32</td>
<td>46</td>
<td>37</td>
<td>23</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>9.0-9.4</td>
<td>80</td>
<td>86</td>
<td>87</td>
<td>73</td>
<td>42</td>
<td>20</td>
</tr>
<tr>
<td>8.5-8.9</td>
<td>267</td>
<td>227</td>
<td>219</td>
<td>184</td>
<td>86</td>
<td>32</td>
</tr>
<tr>
<td>8.0-8.4</td>
<td>314</td>
<td>274</td>
<td>316</td>
<td>345</td>
<td>166</td>
<td>93</td>
</tr>
</tbody>
</table>

AIM: The goal is to improve inpatient, non-operative PRBC transfusion by 20% utilizing 2012 guidelines by December 2016 and 2017.

- Since the implementation of the review process, PRBC transfusions have decreased by 49% in 2016 and by 71% in 2017 in patients with hemoglobin 8-12 g/dL.
- The total number of transfusions performed in 2016 and 2017 was lower.
- The case-mix index was utilized to assess the complexity of the patient and was found to not be a significant contributor.
CONCLUSION
SUMMARY

• A 2 distinct tiers of hemoglobin triggers for RBC transfusions: hemoglobin concentration of less than 7 g/dL for stable, adult inpatients including those in the intensive care unit, and hemoglobin concentration of less than 8 g/dL for a select group of post-surgery patients or those with preexisting cardiac disease.

• It is recommended that institutions develop Massive Transfusion Protocols (MTP) that included dose, timing and ratio of blood component therapy for use in trauma patients with, or at risk of, critical bleeding requiring massive transfusion.

• Blood component transfusion recommendations are:
  • FFP: 15mL/kg
  • Platelets: 1 adult therapeutic dose
  • Cryoprecipitate: 3 – 4 g


• 10. Napolitano LM, Kurek S, Luchette FA, et al; American College of Critical Care Medicine of the Society of Critical Care Medicine; Eastern